CA 125 Elevation in Breast Cancer: A Case Report and Review of the Literature

Breast Journal

Volumn 10, Issue 2, 2004, Pages 146-149

  Leonard, Gregory D ^a   Low, Jennifer A ^a   Berman, Arlene W ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Inflammatory; Metastatic; Ovary; Tumor marker

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CA 125 ANTIGEN; DOCETAXEL; DOXORUBICIN; TUMOR MARKER;

AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ERYTHEMA; FEMALE; HUMAN; LAPAROSCOPY; LYMPH NODE METASTASIS; MAMMOGRAPHY; ONCOGENE NEU; OVARY CANCER; POSTMENOPAUSE; UTERUS MYOMA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; DOXORUBICIN; EDEMA; FEMALE; HUMANS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 1642304085     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21374.x     Document Type: Article

References (22)

1. Meyer T, Rustin GJS. Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-38.
2. Buamah P. Benign conditions associated with raised serum CA 125 concentration. J Surg Oncol 2000;75:264-65.
3. Bast RC, Ravdin P, Hayes D, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
4. Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-37.
5. Kabawat SE, Bast RC, Bhan AK, et al. Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:275-85.
6. Nouwen EJ, Pollet DE, Eerdekens MW, et al. Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 1986;46:866-76.
7. Harǧardöitter H, Parmley TH, Quirk JG, et al. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 1990;163:1925-31.
8. Ögmundsdöttir HM, Gudlaugsdöttir S, Björnsson J, et al. Altered expression of CA-125 in breast carcinomas. APMIS 1996;104:47-53.
9. Omar YT, Behbehani AE, al Naqeeb N, et al. Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer. Int J Biol Markers 1989;4:81-86.
10. Berruti A, Tampellini M, Torta M, et al. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994;30A:2082-84.
11. Jager W, Kissing A, Cilaci S, et al. Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases? Br J Cancer 1994;70:493-95.
12. Krämer S, Jäger W, Lang N. CA 125 is an indicator for pleural metastases in breast cancer. Anticancer Res 1997;17:2967-70.
13. Norum LF, Erikstein B, Nustad K. Elevated CA 125 in breast cancer-a sign of advanced disease. Tumor Biol 2001;22:223-28.
14. Jensen JL, Maclean GD, Suresh MR, et al. Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management. Int J Biol Markers 1990;6:1-6.
15. Perey L, Hayes DF, Tondini C, et al. Elevated CA 125 levels in patients with metastatic breast carcinoma. Br J Cancer 1990;62:668-70.
16. Seckl MJ, Rustin GJS, Coombes RC. CA-125 is not a useful marker in metastatic breast cancer. Br J Cancer 1992;66:875-76.
17. Kawahara M, Terasaki PI, Chia D, et al. Use of four monoclonal antibodies to detect tumor markers. Cancer 1986;58:2008-12.
18. Haga Y, Sakamoto K, Egami H, et al. Clinical significance of serum CA 125 values in patients with cancers of the digestive system. Am J Med Sci 1986;292:30-34.
19. Schenken IL, Pugh RP, Dalbow MH, et al. Diversity of antigenic expression in patients with breast tumors: serum and tissue levels of CA 19.9, CA 125, and CEA antigens [abstract 623]. Proc Am Assoc Cancer Res 1986;27:157.
20. Böhmer CH, Jäger W, Lang N. CA 125 measurement in the follow-up of breast cancer patients. Anticancer Res 1997;17:3099-100.
21. De Wit R, Hoek J, Bakker PJM, et al. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites. J Intern Med 1991;5:463-66.
22. Aydiner A, Topuz E, Dişçi R, et al. Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncol 1994;2:181-86.